{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 90,
  "pageCount": 93,
  "prevPage": 89,
  "nextPage": 91,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The table uses a heatmap-style color coding (red/green) to indicate risk levels.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/90",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-90",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "We predict that selectivity over UGT1A1 could be an issue for some clinical stage MALT1 inhibitors. Inhibition of UGT1A1 mediates bilirubin glucuronidation, potentially leading to hyperbilirubinaemia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "003943a6-6099-4d85-8858-c81035830860",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.42,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "‘565 has a low risk of potential DDI/ hyperbilirubinaemia at predicted human efficacious doses. Potential for safer dose escalation for ‘565 to reach the level of target engagement necessary to achieve clinical efficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aa19805-c604-44a2-8f2f-44b44fcec115",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023. 1) Hertzberg et al. Hematol Oncol, 2023; Cmax,u: Predicted maximum free plasma; Imax,u,inlet: free liver inlet concentration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24b3b875-05ae-4dd5-95d7-b865f99840c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.6
      },
      "kind": "table",
      "text": "Comparison table of Pharma Phase 1b vs '565 across UGT1A1 metrics",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57fd23ae-68bf-459a-b4f6-53ca8a5ae0a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Potential safety benefit compared with clinical MALT1i in development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6a5aef1-3a92-4207-b4fb-c4e4eb54e264",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 has a low predicted risk of hyperbilirubinaemia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9d90cae-e0f9-454d-9eca-32bc87e1cb54",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "33669923-f7d2-401c-b157-87fbbe90ed69",
      "evidence": "Direct comparison of two compounds across multiple safety metrics",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}